Effects of different resistance mechanisms on bacterial response to meropenem, ciprofloxacin, and their combination described by next-generation mechanism-based modelling.

Analysis of intrahospital and global dissemination and resistome dynamics of NDM-1-producing ST773 Pseudomonas aeruginosa high-risk clone.

Ceftazidime-avibactam use selects multidrug-resistance and prevents designing collateral sensitivity-based therapies against Pseudomonas aeruginosa.

Whole Genome Sequencing Analysis of Klebsiella pneumoniae Isolates from Health Care-Associated Bacteremia of Urinary Origin in Spain: Findings from the Multicenter ITUBRAS-2 Cohort Study.

Pseudomonas aeruginosa chronic infections in patients with bronchiectasis: a silent reservoir of carbapenemase-producing epidemic high-risk clones.

Rapid prediction of carbapenemases in Pseudomonas aeruginosa by imipenem/relebactam and MALDI-TOF MS.

Emerging resistance mechanisms to newer β-lactams in Pseudomonas aeruginosa.

Ceftazidime-avibactam plus aztreonam cocktail for the treatment of VIM-producing Pseudomonas aeruginosa infections: good enough to have another?

Mutant prevention concentrations and phenotypic and genomic profiling of first-step resistance mechanisms to classical and novel β-lactams in Pseudomonas aeruginosa.

How do I manage difficult-to-treat Pseudomonas aeruginosa infections? Key questions for today’s clinicians.